Krishna Institute of Medical Sciences Limited
All news and filings related to Krishna Institute of Medical Sciences Limited.
View all news & filings- Medium impact
KIMS enters 5-year Operations & Management Agreement with Sarvottam Health Care
KIMS has signed a 5-year Operations and Management Agreement with Sarvottam Health Care Private Limited. KIMS will manage the hospital and receive 9% of its net revenue. This move expands KIMS' presence in Andhra Pradesh.
Read the summary - Low impact
KIMS to hold Investor Meeting on Sep 10, 2026 with Emkay Global
Krishna Institute of Medical Sciences Limited (KIMS) will hold an Institutional Investor Meeting on September 10, 2026, hosted by Emkay Global. The meeting will take place in person at KIMS Mahadevpura and will be based on publicly available information.
Read the summary - Medium impact
KIMS: Voting Results of 24th AGM on Aug 27, 2026, with Strong Shareholder Approval
KIMS announced voting results for its 24th AGM held on August 27, 2026. Shareholders approved audited financial statements for FY26, re-appointed Ms. Dandamudi Anitha as Director, and ratified cost auditor remuneration. Special resolutions for loans/guarantees under Section 185 and overall limits under Section 186 were also passed.
Read the summary - Low impact
KIMS Holds 24th AGM on Aug 27, 2026, Transacts Business as Notified
Krishna Institute of Medical Sciences Limited (KIMS) conducted its 24th Annual General Meeting (AGM) on August 27, 2026. The meeting transacted ordinary and special businesses, including the adoption of FY26 financial statements and approvals for loans and investments. Voting results will be shared soon.
Read the summary - Medium impact
KIMS Denies Acquisition Talks with Renova Hospitals for $52 Million
KIMS denies reports of talks to acquire a stake in Renova Hospitals for $52 million. The company states the news is false, baseless, and factually incorrect, confirming no agreement or discussions have taken place.
Read the summary - Medium impact
KIMS Signs O&M and Call Option Agreements with Aurevia Hospitals
KIMS has signed an Operations and Management Agreement and a Call Option Agreement with Aurevia Hospitals Private Limited (AHPL). KIMS will manage Arete Hospitals for an initial 5-year term, receiving 9% of Net Revenue. The Call Option Agreement allows KIMS to acquire the business if suitable.
Read the summary - Medium impact
KIMS Allots 77 Lakh Warrants to Promoters for ₹150 Crore
KIMS has allotted 77,02,182 warrants on a preferential basis to promoters Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP. The company received ₹149.99 crore as subscription money (25% of the issue price). Warrants are convertible into equity shares within 18 months.
Read the summary - High impact
KIMS Hospitals Q1 FY27 Earnings Call Transcript Released
KIMS Hospitals reported Q1 FY'27 revenue of ₹1,196 crore, up 36.1% YoY, and EBITDA of ₹240 crore, up 20.1% YoY. PAT was ₹37 crore. The company raised ₹1,500 crore via QIP, using ₹1,100 crore for debt reduction, and ₹600 crore via preferential allotment to promoters. New units in Palakkad, Kerala opened, and Bangalore units are showing positive ramp-up.
Read the summary - Medium impact
KIMS Receives In-Principle Approval for Preferential Issue of 77 Lakh Warrants
KIMS received in-principle approval from BSE and NSE for issuing 77,02,182 warrants to promoters/promoter group on a preferential basis. These warrants are convertible into equity shares of face value ₹2 each. The approval is conditional upon fulfilling various regulatory compliances and strengthening internal controls.
Read the summary - Low impact
KIMS Announces 24th AGM on August 27, 2026, via Video Conference
Krishna Institute of Medical Sciences Limited (KIMS) will hold its 24th Annual General Meeting (AGM) on August 27, 2026. The meeting will be conducted virtually via Video Conference/Other Audio Visual Means.
Read the summary - Low impact
KIMS Schedules 24th AGM for August 27, 2026, via VC/OAVM
Krishna Institute of Medical Sciences Limited will hold its 24th AGM on August 27, 2026, at 4:00 PM IST via VC/OAVM. The company is also reminding shareholders to update KYC details and dematerialize physical securities as per SEBI regulations.
Read the summary - Low impact
KIMS Submits FY26 BRSR Report with Reasonable Assurance
Krishna Institute of Medical Sciences Limited (KIMS) has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26. The report, along with a Reasonable Assurance Report from M/s. Brahmayya & Co., details the company's commitment to ESG principles. It covers environmental, social, and governance practices.
Read the summary - Medium impact
KIMS Submits FY26 Integrated Annual Report, Highlights Expansion and Financial Initiatives
KIMS submitted its FY26 Integrated Annual Report. Consolidated revenue grew 28.2% to ₹39,308 million. EBITDA rose 1.6% to ₹8,282 million, while PAT fell 41.7% to ₹2,420 million due to expansion costs. The company raised ₹1,500 crore via QIP, using ₹1,100 crore for debt reduction, and ₹600 crore through promoter preferential allotment.
Read the summary - Medium impact
KIMS Announces 24th AGM on Aug 27, 2026, to Discuss FY26 Financials & Director Re-appointment
Krishna Institute of Medical Sciences Limited (KIMS) will hold its 24th AGM on August 27, 2026, via VC/OAVM. The meeting will adopt audited standalone and consolidated financial statements for FY26 and re-appoint Director Ms. Dandamudi Anitha. Members will also vote on approving loans/guarantees up to ₹650 crore and ratifying cost auditor remuneration.
Read the summary - Low impact
KIMS Releases Q1 FY27 Conference Call Audio Recording
Krishna Institute of Medical Sciences Limited (KIMS) has made the audio recording of its Q1 FY27 investor and analyst conference call available. The call was held on August 7, 2025. The recording is accessible on the company's website.
Read the summary - Low impact
KIMS Schedules Analyst/Institutional Investor Meeting on August 12, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will attend the Emkay Confluence 2026 event in Mumbai on August 12, 2026. The company will participate in a group meeting with analysts and institutional investors. No unpublished price-sensitive information will be disclosed.
Read the summary - Low impact
KIMS Hospitals Publishes Q1 FY27 Unaudited Financial Results in Newspapers
KIMS Hospitals has published its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were published in the Financial Express and Navatelangana newspapers as per SEBI regulations. The company is also pursuing various project approvals and emphasizing environmental sustainability.
Read the summary - Low impact
KIMS Q1FY27 Monitoring Agency Report: ₹1,500 Crore QIP Utilization Reviewed
Krishna Institute of Medical Sciences Limited's QIP of ₹1,500 crore shows ₹1,086.49 crore utilized by June 30, 2026. Funds were used for debt repayment (₹910 crore) and subsidiary investments (₹130 crore). Unutilized ₹413.51 crore is in money market funds. No material deviations were reported.
Read the summary - Low impact
KIMS Reports NIL Deviation in QIP Fund Utilization for Q1 FY27
Krishna Institute of Medical Sciences Limited reported NIL deviation in QIP fund utilization for the quarter ended June 30, 2026. Total funds raised were ₹1500 crore on June 19, 2026. Utilized amount was ₹1086.49 crore for debt repayment and investments.
Read the summary - Medium impact
KIMS Hospitals Q1 FY27 Revenue Surges 36.1% YoY to ₹1,196 Cr; PAT Declines
KIMS Hospitals reported Q1 FY27 consolidated revenue of ₹1,196 crore, up 36.1% YoY. EBITDA rose 20.1% YoY to ₹240 crore. However, PAT declined 56.5% YoY to ₹37 crore, with EPS at ₹1.04. Cash and equivalents were ₹505 crore. The company added a new hospital in Palakkad.
Read the summary - High impact
KIMS Reports Q1 FY27 Results: Revenue Up 35.3% YoY to ₹11,795 Million, EBITDA Rises 20.1%
KIMS reported Q1 FY27 operating revenue of ₹11,795 million (₹1,179.5 crore), up 35.3% YoY. EBITDA rose 20.1% to ₹2,398 million (₹239.8 crore). IP volume increased by 26.6% and OP volume by 8.0%. ARPOB grew 9.7% to ₹47,200. The company added 787 beds in Kondapur and 208 in Palakkad.
Read the summary - Medium impact
KIMS Approves Loan Facility of ₹650 Cr, Q1 FY27 Results Declared
KIMS declared its Q1 FY27 unaudited results. The Board approved advancing loans up to ₹650 Cr to subsidiaries and ₹25 Cr to KIMS Hospital Enterprises Private Limited. Draft O&M and Call Option Agreements were also approved with Golden Lan Solutions and Sarwottam Healthcare.
Read the summary - Low impact
KIMS to Host Analyst Call on Aug 4th to Discuss Q1FY27 Strategy Post Results
KIMS Hospitals will host a conference call on August 4, 2026, at 10:00 am IST. Management will discuss business strategy and outlook post Q1FY27 financial results. Key participants include Dr. Bhaskara Rao Bollineni, Dr. Abhinay Bollineni, and Mr. Sachin Salvi.
Read the summary - Low impact
KIMS Files SEBI Compliance Certificate for Q1 FY27
Krishna Institute of Medical Sciences Limited (KIMS) has submitted a SEBI compliance certificate for the quarter ended June 30, 2026. The certificate confirms the processing of dematerialisation requests by the Registrar and Share Transfer Agent, MUFG Intime India Private Limited.
Read the summary - Medium impact
KIMS: EGM Approves Preferential Allotment of Warrants and Executive Director Change
KIMS shareholders approved the preferential issuance of 77,02,182 warrants and the change of Mr. Adwik Bollineni's designation to Executive Director. Both resolutions passed with significant majorities at the EGM held on July 9, 2026.
Read the summary - Low impact
KIMS Hospitals Announces Corrigendum to EGM Notice for Meeting on July 9
Krishna Institute of Medical Sciences Limited (KIMS) announced a corrigendum to the Notice of its Extraordinary General Meeting (EGM). The EGM is scheduled for Thursday, July 9, 2026, to be conducted via Video Conferencing. Newspaper advertisements regarding the corrigendum were published on July 5, 2026.
Read the summary - Medium impact
KIMS Issues Corrigendum for EGM Notice Regarding Preferential Issue
KIMS has issued a corrigendum to its EGM notice for a preferential issue. The EGM is scheduled for July 9, 2026. The corrigendum clarifies updated debt repayment amounts totaling ₹3,42,79,59,983 and confirms the promoter status of Dr. Abhinay Bollineni, Mr. Adwik Bollineni, and Bharas Ventures LLP.
Read the summary - Medium impact
KIMS Issues Corrigendum to EGM Notice for Preferential Issue
Krishna Institute of Medical Sciences Limited (KIMS) issued a corrigendum to its EGM notice concerning a proposed preferential issue of equity shares. The EGM is scheduled for July 9, 2026. The corrigendum addresses clarifications requested by NSE and rectifies typographical errors.
Read the summary - Low impact
KIMS: Trading Window Closed from July 1 for Q1 FY27 Results
KIMS will close its trading window from July 1, 2026, for Q1 FY27 financial results. The window will reopen 48 hours after results declaration. Directors and insiders are restricted from trading during this period.
Read the summary - Low impact
KIMS Receives Listing Approval for 1.98 Crore Equity Shares via QIP
Krishna Institute of Medical Sciences Limited (KIMS) has received listing approval from BSE and NSE for 1,98,67,549 equity shares issued via Qualified Institutional Placement (QIP). The shares have a face value of Rs. 2 each.
Read the summary - High impact
KIMS Raises ₹1500 Crore via QIP at ₹755/Share
KIMS raised approximately ₹1,500 crore through a Qualified Institutions Placement (QIP). The company allotted 1,98,67,549 equity shares at ₹755 per share. The QIP opened on June 16, 2026, and closed on June 19, 2026. This issuance increases the company's paid-up equity share capital.
Read the summary - Medium impact
KIMS Closes QIP, Allots 1.98 Cr Shares at ₹755 Each, Raising Funds
Krishna Institute of Medical Sciences Limited (KIMS) closed its Qualified Institutions Placement (QIP) on June 19, 2026. The company allocated 19,867,549 equity shares at ₹755 per share, including a discount. The QIP issue opened on June 16, 2026.
Read the summary - Medium impact
KIMS Allocates 1.98 Cr Shares via QIP at ₹755/Share, Raises Funds
KIMS has closed its QIP issue on June 19, 2026, allocating 19,867,549 equity shares at ₹755 per share. The issue opened on June 16, 2026. The company approved the placement document and allocation notes.
Read the summary - Low impact
KIMS Announces EGM on July 9, 2026, to be held via Video Conferencing
Krishna Institute of Medical Sciences Limited (KIMS) will hold an Extraordinary General Meeting (EGM) on July 9, 2026. The meeting will be conducted via Video Conferencing/Other Audio Visual Means.
Read the summary - Medium impact
KIMS Approves Qualified Institutions Placement with Floor Price of ₹771.73
Krishna Institute of Medical Sciences Limited (KIMS) has approved a Qualified Institutions Placement (QIP) with a floor price of ₹771.73 per equity share. The issue opened on June 16, 2026. A meeting on June 19, 2026, will finalize the issue price. The trading window is closed.
Read the summary - Low impact
KIMS Files Audited FY26 Standalone & Consolidated Financial Results
Krishna Institute of Medical Sciences Limited (KIMS) has filed its audited standalone and consolidated financial statements for the financial year ended March 31, 2026. The results were approved by the Board on May 15, 2026, and are now subject to shareholder adoption at the AGM. The company's statutory auditors have confirmed adequate internal financial controls.
Read the summary - High impact
KIMS Approves ₹600 Crore Preferential Allotment of Warrants to Promoters
KIMS approved issuing 77.02 lakh warrants convertible into equity shares at ₹779 each to promoters for ₹599.99 crore. An EGM is scheduled for 09 July 2026 to seek shareholder approval. Warrants are exercisable within 18 months.
Read the summary - Low impact
KIMS Promoter Group Declares No New Share Encumbrances
Krishna Institute of Medical Sciences Limited's promoter group, led by Dr. Bhaskara Rao Bollineni, declared no new share encumbrances as of April 8, 2026. Existing pledges include 10,50,99,645 shares by Dr. Bollineni and 2,42,03,310 shares by Bluebridge Capital Private Limited.
Read the summary - Low impact
KIMS Schedules Analyst/Institutional Investor Meeting for August 13, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will hold an Analyst/Institutional Investor Group Meeting on August 13, 2026, in Mumbai. No Unpublished Price Sensitive Information will be disclosed.
Read the summary - Low impact
KIMS to hold investor meetings on June 4, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will conduct one-on-one meetings with analysts and institutional investors on June 4, 2026. The discussions will focus on publicly available information and the general business outlook, without disclosing any unpublished price sensitive information.
Read the summary - Medium impact
KIMS Hospitals Q4 FY'26 Earnings Call Transcript Released
KIMS Hospitals released its Q4 FY'26 earnings call transcript. Q4 revenue reached ₹1,084 crore (up 35.3% YoY), with EBITDA at ₹216 crore (up 6.8% YoY). FY'26 revenue was ₹3,931 crore (up 28.2% YoY), with EBITDA at ₹828 crore (up 1.6% YoY). The company plans a ₹1,500 crore QIP to reduce debt and fund expansions. New units are contributing to growth, with ongoing focus on operational efficiency and market penetration.
Read the summary - Low impact
KIMS Schedules Investor Meetings from May 25-29, 2026
Krishna Institute of Medical Sciences Limited (KIMS) will hold meetings with analysts and institutional investors from May 25 to May 29, 2026. No unpublished price-sensitive information will be disclosed during these sessions.
Read the summary - Low impact
KIMS: Audio Recording of Q4 FY26 Investor Conference Call Available Online
Krishna Institute of Medical Sciences Limited has made the audio recording of its Q4 FY26 investor conference call, held on May 12, 2026, available on its website. The recording can be found in the investor relations section under disclosures.
Read the summary - Medium impact
KIMS Hospitals Q4 FY26 Revenue Surges 35% YoY to ₹1,084 Cr, PAT at ₹33 Cr
KIMS Hospitals reported Q4 FY26 consolidated revenue of ₹1,084 Cr (up 35.3% YoY) and EBITDA of ₹216 Cr (up 6.8% YoY). PAT was ₹33 Cr. For FY26, revenue was ₹3,931 Cr (up 28.2% YoY) with PAT at ₹242 Cr. ARPOB grew 13.7% and ARPP grew 14% in Q4 FY26.
Read the summary - Medium impact
KIMS Announces Investor Presentation for FY26 Audited Results
KIMS Hospitals released its audited FY26 results presentation. FY26 revenue reached ₹3,930.8 crore, with EBITDA at ₹828.2 crore and PAT at ₹242.0 crore. The company highlighted its growth strategy, regional performance, and operational metrics, including bed capacity and occupancy rates.
Read the summary - Low impact
KIMS Hospitals Files Audited Financial Results for Q4FY26
Krishna Institute of Medical Sciences Limited (KIMS) has published its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company is also actively involved in the "Vidyadaan" initiative, providing digital education resources. Expansion projects and service enhancements are ongoing across its hospital network.
Read the summary - Medium impact
KIMS Appoints Cost Auditors, Senior Management, and Re-designates Adwik Bollineni
Krishna Institute of Medical Sciences Limited (KIMS) appointed M/s. Sagar & Associates as Cost Auditors for FY 2026-27. The company also appointed Sachin Ashok Salvi as CFO, Nagajayanthi J.R. as Company Secretary & Compliance Officer, and Bhaskar Reddy R.K. as Chief Risk Officer & Chief Internal Audit. Adwik Bollineni was re-designated from Non-Executive to Executive Director.
Read the summary - Medium impact
KIMS Approves FY26 Audited Results, Appoints Cost Auditors, and Expands Senior Management
KIMS' Board approved FY26 audited standalone and consolidated results for the quarter ended March 31, 2026. Cost Auditors were appointed for FY27. New Senior Management Personnel, including a CFO and Company Secretary, were identified. Mr. Adwik Bollineni was redesignated to Executive Director. The 24th AGM is set for August 27, 2026.
Read the summary - Medium impact
KIMS Board Approves Audited FY26 Results; Appoints Cost Auditors, Senior Management
KIMS Board approved audited FY26 results for the quarter and year ended March 31, 2026. Appointed Sagar & Associates as Cost Auditors for FY27. Identified Sachin Ashok Salvi (CFO), Nagajayanthi J.R (Company Secretary), and Bhaskar Reddy R.K (CRO) as Senior Management Personnel. Re-designated Adwik Bollineni as Executive Director. The 24th AGM will be held on August 27, 2026.
Read the summary - Low impact
KIMS to hold Investor Meetings from May 18-22, 2026
Krishna Institute of Medical Sciences Limited will conduct investor meetings from May 18 to May 22, 2026. The discussions will revolve around general business outlook and publicly available information, with no UPSI disclosure planned.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio - Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio